Peptide Clinical Trials: Phase 1-3 Development Strategy, Endpoints, and Regulatory Submission 2026

Industry Authority | 2026-07-10 | 13 min read

A 2026 industry guide to peptide clinical trials: Phase 1-3 development strategy, endpoint selection, patient population, regulatory submission, and accelerated pathways.

Introduction: the clinical development journey

Clinical development transforms a peptide from a laboratory compound to an approved drug. This journey spans 6-10 years and requires careful planning, execution, and regulatory navigation.

This 2026 guide covers the clinical development strategy for peptide therapeutics.

Phase 1: First-in-human studies

Objectives

Phase 1 establishes:

• Safety and tolerability
• Pharmacokinetic profile
• Maximum tolerated dose (MTD)
• Dose-escalation strategy

Study design

| Design Element | Typical Approach | | --- | --- | | Population | Healthy volunteers (unless unsafe) | | Sample size | 20-100 subjects | | Dosing | Single ascending dose (SAD) | | Duration | 4-8 weeks per cohort | | Endpoints | Safety, PK, immunogenicity |

PK parameters

Phase 1 PK characterization includes:

• Cmax (maximum concentration)
• Tmax (time to maximum)
• AUC (area under curve)
• Half-life (t1/2)
• Clearance (CL)
• Volume of distribution (Vd)
• Bioavailability (for non-IV routes)

Special considerations for peptides

• Subcutaneous vs. IV PK comparison
• Bioavailability for oral peptides (often <1%)
• Dose selection for Phase 2 based on PK/PD modeling
• Immunogenicity monitoring from Day 1

Phase 2: Efficacy and dose-finding

Objectives

Phase 2 establishes:

• Preliminary efficacy
• Optimal dose selection
• Patient population definition
• Clinical proof of concept

Study designs

| Design | Use Case | | --- | --- | | Parallel group | Standard efficacy confirmation | | Cross-over | Conditions with washout | | Factorial | Combination therapy | | Adaptive | Seamless Phase 2/3 |

Dose selection

Phase 2 doses are selected based on:

• Phase 1 safety and PK data
• Preclinical efficacy models
• PK/PD modeling
• Target engagement biomarkers

Typically 2-4 dose levels tested in Phase 2.

Efficacy endpoints

| Indication | Primary Endpoint | Secondary Endpoints | | --- | --- | --- | | Type 2 Diabetes | HbA1c change | Fasting glucose, weight, hypoglycemia | | Obesity | Body weight % change | Waist circumference, metabolic markers | | MASH | MASH resolution + fibrosis | Liver fat, ALT, MRI-PDFF | | Cardiovascular | MACE events | Lipids, biomarkers |

Phase 3: Confirmatory trials

Objectives

Phase 3 provides definitive evidence of:

• Efficacy in intended population
• Safety over longer duration
• Benefit/risk profile for approval

Study design

Phase 3 trials are typically:

• Randomized (1:1 or 2:1)
• Double-blind
• Placebo-controlled (or active comparator)
• Multi-center (50-200 sites)
• Large sample size (500-5,000 patients)

Regulatory requirements

FDA and EMA require:

• Two adequate and well-controlled trials (or one trial + confirmatory evidence)
• Pivotal endpoints that are clinically meaningful
• Adequate safety database (typically 500-1,000 patients)
• Consistent results across trials

Statistical analysis

Statistical analysis plan (SAP) must be pre-specified:

• Primary endpoint analysis
• Multiple comparison procedures
• Subgroup analyses
• Missing data handling
• Sensitivity analyses

Regulatory submissions

US: New Drug Application (NDA)

NDA structure:

• Executive summary
• CMC (chemistry, manufacturing, controls)
• Nonclinical pharmacology/toxicology
• Clinical pharmacology
• Clinical efficacy (all Phase 1-3 studies)
• Clinical safety (all Phase 1-3 studies)
• Clinical statistics
• Labeling

Review timeline: 10-12 months (standard), 6 months (priority review).

EU: Marketing Authorization Application (MAA)

MAA structure (eCTD format):

• Administrative and product information
• Quality (CMC)
• Nonclinical (pharmacology, toxicology)
• Clinical (pharmacology, efficacy, safety)

Review timeline: 12-18 months (standard), accelerated assessment available.

Accelerated pathways

Accelerated approval (US)

For serious conditions with unmet need:

• Approval based on surrogate endpoint
• Post-marketing confirmatory trials required
• Typical time savings: 1-2 years

PRIME scheme (EU)

For medicines targeting unmet medical needs:

• Enhanced interaction with EMA
• Accelerated assessment available
• Tailored development guidance

Breakthrough therapy designation (US)

For drugs showing substantial improvement:

• Intensive FDA guidance
• Rolling review
• Typically for serious diseases

Biomarkers in clinical development

Biomarker types

| Type | Use | | --- | --- | | Diagnostic | Patient selection | | Pharmacodynamic | Target engagement | | Predictive | Responders vs. non-responders | | Monitoring | Safety monitoring | | Prognostic | Disease progression |

Biomarker-driven development

Biomarkers enable:

• Patient stratification (responders vs. non-responders)
• Dose selection (optimal target engagement)
• Early go/no-go decisions
• Enrichment strategies

Clinical safety monitoring

Safety endpoints

| Endpoint | Definition | | --- | --- | | Adverse events (AE) | Any untoward medical occurrence | | Serious adverse events (SAE) | Death, hospitalization, disability, life-threatening | | Adverse drug reactions (ADR) | Causally related AEs |

Safety monitoring plan

Clinical trials require:

• DSMB (Data Safety Monitoring Board)
• Safety reporting (SAE within 24 hours)
• Annual safety updates
• Post-marketing surveillance (Phase 4)

Summary

Clinical development is a multi-year journey from first-in-human to regulatory approval. Phase 1 establishes safety, Phase 2 identifies optimal dose, Phase 3 confirms efficacy, and regulatory submission secures approval. Accelerated pathways can shorten timelines for drugs addressing unmet needs.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.